The minor cannabinoid industry has seen exponential year over year growth. In the past few years, products containing minor cannabinoids such as CBN and CBG have been flying off the shelf at fast speed. Right now, we’re seeing a continuation of this trend of growing minor cannabinoid interest, but it’s evolving and new products are becoming available. Below, we’ve discussed some of the leading minor cannabinoid trends for 2022 and what the future could bring for cannabis brands that are bold enough to brave new frontiers.
Minor Cannabinoid Market Growth
According to a market analysis report conducted by Grand View Research, the U.S. minor cannabinoids market size was valued at 4.9 billion dollars in 2020. By the year 2028, the market is expected to expand at a compound annual growth rate (CAGR) of 20.1% and reach 26.2 billion dollars.
Sales from CBN and CBG products saw tremendous growth between 2021 and 2022, increasing as much as 1100-1200% in certain U.S. states. Additionally, CBDA and CBC are on the rise, and dozens of other cannabinoids have yet to be explored. Market growth is expected to be amplified by continuing research and acceptance among the scientific and medical communities.
Minor Cannabinoid Trends in 2022
While many canna-businesses have already cashed-in on the CBN and CBG booms, some minor cannabinoid markets are still at emergent stages. Others have yet to be explored entirely. Here are some of the top minor cannabinoid trends that occurred in 2022:
CBDA - Cannabidiolic acid
This year, we saw a tremendous increase in the number of companies offering CBDA products. This includes CBDA tinctures, topicals, and capsules. CBDA (Cannabidiolic acid) is the chemical precursor to cannabidiol. Like CBD, it is non psychoactive. Early studies have suggested that CBDA may have the ability to reduce seizures, reduce tumors, and treat inflammation.
CBC - Cannabichromene
Another trend we saw in 2022 was the rise of CBC products. CBC is believed to bind with key bodily receptors linked to pain such as the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1). CBD may also have a positive effect on neural stem progenitor cells (NSPCs), a cell essential to healthy brain function, and could also potentially inhibit cancer cell growth, alleviate depression, and inhibit acne.
THCV - Tetrahydrocannabivarin
2022 also saw the emergence of THCV products. Currently, most brands are choosing to market these products as potential appetite suppressant and weight-loss aids. Tetrahydrocannabivarin is a minor cannabinoid that is similar to Δ9-tetrahydrocannabinol, but has slightly different properties. Some studies with rodents have suggested that THCV may have the ability to affect appetite, increase satiety, and regulate metabolic functions.
CBDV - Cannabidivarin
CBDV is a minor cannabinoid that is structurally similar to CBDV. Much of early research around CBDV has focused on seizures. Early studies suggest that CBDV may affect the neurochemical pathway of the capsaicin receptors involved in epilepsy.
Opportunity Is Knocking in the Minor Cannabinoid Market
If you’re a cannabis brand and have been thinking about expanding your product line, now may be your chance to enter the minor cannabinoid market and start taking advantage of some of the emerging minor cannabinoid trends. Now could be your chance to get in on the ground floor. Contact us today to learn more about our custom CBD product formulation and manufacturing services.
